Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

181.68 +4.24 (+2.39%)
Official Closing Price Updated: 4:10 PM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
80 81 Next >
Small Caps Are On A Tear Including Speculative Biotechs
So far 2023 is going well with our game plan -an end-of-year seasonal rally coupled with a run in speculative biotechs driven by innovation. 
Via Talk Markets
AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why
The acquisition fills an immediate need with some extras to boot. 
Via The Motley Fool
29 Undervalued Dividend Aristocrats: December 2023
The S&P 500 Dividend Aristocrats Index contains 67 dividend growth stocks called the Dividend Aristocrats. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Market Whales and Their Recent Bets on ABBV Options
Via Benzinga
AbbVie Inc. (NYSE: ABBV) Highlighted for Surprising Price Action
Via Investor Brand Network
$100 Invested In This Stock 10 Years Ago Would Be Worth $300 Today
Via Benzinga
8 Analysts Have This to Say About AbbVie
Via Benzinga
Better Income Stock: AT&T or AbbVie?
These two blue chips are highly prized for their top-shelf dividend programs. 
Via The Motley Fool
Decoding AbbVie's Options Activity: What's the Big Picture?
Via Benzinga
Better Growth Stock: AbbVie vs. Abbott Laboratories
Do Humira's declining sales give Abbott Laboratories the edge as the better growth stock? 
Via The Motley Fool
7 Blue-Chip Dividend Stocks to Buy Before Dec. 31
Always a strong investment, blue-chip dividend stocks continue to make sense as 2023 draws closer to an end and 2024 nears. 
Via InvestorPlace
7 ‘Bulletproof’ Stocks to Buy Ahead of a Wild New Year
If you don’t quite trust the hyper-bullish narrative, these ideas can help boost confidence. 
Via InvestorPlace
Stock(ing) Stuffers That Could Be Lovin The High 2024
Via Talk Markets
Healthcare Sector Stocks: Consistent Above-Average Growth And Income
The healthcare sector is full of many really good companies with consistent, long term, above-average growth rates and many that have good, consistent, long-term dividend records. 
Via Talk Markets
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
Via Benzinga
3 of the Most Attractive Dividend Stocks in the Pharma Space
Discover the resilience and growth potential of pharma dividend stocks, offering stability and consistency in the healthcare sphere. 
Via InvestorPlace
Dividend Income Update For November 2023
It’s dividend income update time. This is one of my favorite times of the month, as I get to review the previous month of passive income received from my dividend income portfolio. 
Via Talk Markets
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
These stocks could bring investors more than just a lump of coal for Christmas. 
Via The Motley Fool
Exposures Coal
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The 7 Most Undervalued Growth Stocks to Buy in December
Buy these distressed names now and ride their share prices higher over the coming year as they stage a comeback. 
Via InvestorPlace
Economic Safety Nets: 7 Defensive Stocks Providing Portfolio Stability
Although some signs of economic progress is seen, other signs suggest that investors should consider defensive stock picks. 
Via InvestorPlace
Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings
Consumer advocacy group Public Citizen has filed a petition with the FDA, urging the agency to demand stronger warnings regarding the risk of a potentially fatal muscle-paralyzing disease linked to... 
Via Benzinga
Exposures Product Safety
AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors
It's making a major acquisition to beef up a key area of its pipeline. 
Via The Motley Fool
Bristol Myers Squibb Further Diversifies Oncology Portfolio With Mega $8.4B Deal
SystImmune and Bristol Myers Squibb & Co (NYSE: BMY)  
Via Benzinga
AbbVie continues shopping spree with biotech buyout
While the diversifying AbbVie appears to be in a state of flux, there is one constant investors can depend on — the dividend. 
Via MarketBeat
Biotech Is Coming Back, Can The Run Last?
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. 
Via Talk Markets
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq – CERE), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
The 3 Best Cheap Stocks to Buy in December
Investors wanting to buy low and sell high should consider a position in one of these great companies whose shares have pulled back lately. 
Via InvestorPlace
4 Top Dividend Stocks Yielding More Than 4% to Buy Hand-Over-Fist This December
These companies offer above-average income streams that should continue rising. 
Via The Motley Fool
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?
The big drugmaker went on a holiday shopping spree. 
Via The Motley Fool
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
80 81 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.